Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 158
Filter
1.
Rev. saúde pública (Online) ; 58: 02, 2024. tab, graf
Article in English | LILACS | ID: biblio-1536767

ABSTRACT

ABSTRACT OBJECTIVE To describe the prevalence of contraindicated use of combined hormonal contraceptives, progesterone-only contraceptives, and intrauterine devices in mothers participating in the 2015 Pelotas Birth Cohort according to the WHO medical eligibility criteria. METHODS The biological mothers of children belonging to the 2015 Pelotas birth cohort who attended the 48-month follow-up were studied. The 48-month follow-up data were collected from January 1, 2019, to December 31, 2019. Contraindicated use of modern contraceptives was considered to occur when these women presented at least one of the contraindications for the use of modern contraceptives and were using these methods. The prevalence of contraindicated use was calculated according to each independent variable and their respective 95% confidence intervals (95%CI). RESULTS The analyzed sample consisted of 3,053 women who used any modern contraceptive method. The prevalence of contraindicated use of modern contraceptives totaled 25.9% (95%CI: 24.4-27.5). Combined hormonal contraceptives showed the highest prevalence of contraindicated use (52.1%; 95%CI: 49.3-54.8). The prevalence of contraindicated use of modern contraceptives methods was greater in women with family income between one and three minimum wages, a 25-30 kg/m2 body mass index, indication by a gynecologist for the used method, and purchasing the contraceptive method at a pharmacy. The higher the women's education, the lower the prevalence of inappropriate use of modern contraceptives. CONCLUSION In total, one in four women used modern contraceptives despite showing at least one contraindication. Policies regarding women's reproductive health should be strengthened.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Progesterone , Contraceptive Agents , Contraceptives, Oral, Combined , Contraindications , Intrauterine Devices
2.
Int. j. cardiovasc. sci. (Impr.) ; 35(4): 500-510, July-Aug. 2022. tab, graf
Article in English | LILACS | ID: biblio-1385267

ABSTRACT

Abstract Background: The use of combined oral contraceptives (COC) is a risk factor for atherosclerotic disease, and physical exercise can minimize this condition. Objective: To verify if high intensity interval training (HIIT) promotes changes in the lipid and inflammatory profile of women using COC. Methods: Sequential crossover study with women aged 20-30 years, classified as irregularly active by the international physical activity questionnaire (IPAQ), when using COC. A physical-clinical assessment was performed with anthropometric measurements, VO2max, and analysis of lipid and inflammatory profile. Participants were divided into 2 groups: the initial intervention group (GII), which began practicing HIIT for 2 months, and the posterior intervention group (GIP), which remained inactive for the same period. The GII and GIP would then alternate their conditions. The collected data was divided into: Initial moment (IM), post-exercise moment (PEM) and post-inactivity (PIM). The statistical analyses were performed using the Statistical Package for the Social Sciences, adopting a significance level of p <0.05 . Results: Twelve women were evaluated. After crossing the GII and GIP data, there was a difference in the C-reactive protein values between the IM of 4 (1.6-6.3 mg/dL) vs. PEM 2 (1.5-5 mg/dL); as well as between the PEM vs. the PIM= 4 (1.5-5.8 mg/dL), with a p -value = 0.04 in the comparisons. There was no change between the "moments" of the lipid profile, although it was possible to notice a reduction in resting HR and an increase in indirect VO2max. Conclusion: The HIIT program was able to reduce the inflammatory profile, but it did not alter the lipid profile of irregularly active women using COC.


Subject(s)
Humans , Female , Adult , Young Adult , Contraceptives, Oral, Combined/adverse effects , Atherosclerosis/prevention & control , High-Intensity Interval Training , Cross-Sectional Studies , Atherosclerosis/etiology , Heart Disease Risk Factors
3.
Femina ; 49(3): 134-141, 2021. ilus
Article in Portuguese | LILACS | ID: biblio-1224073

ABSTRACT

A suspeita clínica de endometriose geralmente envolve a história clínica da paciente e exame físico, abordando sua sintomatologia e história pessoal e familiar. Entretanto, a apresentação clínica da doença varia consideravelmente, sem características clínicas patognomônicas, fato que dificulta o seu diagnóstico. Um diagnóstico presuntivo de endometriose pode ser fortemente sugerido pela ultrassonografia transvaginal e pela ressonância magnética em casos de endometrioma ou endometriose infiltrativa profunda. No entanto, esses exames de imagem não possuem a sensibilidade e a especificidade necessárias quando se trata de endometriose peritoneal superficial. O biomarcador sérico mais utilizado na investigação da endometriose foi o CA-125, que não apresenta sensibilidade (70%-75%) suficiente para sua indicação na prática clínica. Portanto, apesar de seu risco e alto custo, a videolaparoscopia e a análise anatomopatológica subsequente ainda se apresentam como o procedimento padrão-ouro para o diagnóstico definitivo de endometriose. Assim, com o objetivo de demonstrar quais exames seriam necessários para o diagnóstico dessa doença, realizamos uma revisão sistemática da literatura, cujos dados estão descritos a seguir.(AU)


Subject(s)
Humans , Female , Video-Assisted Surgery , Endometriosis/surgery , Endometriosis/etiology , Endometriosis/diagnostic imaging , Progestins/therapeutic use , Contraceptives, Oral, Combined/therapeutic use , Endometriosis/drug therapy , Gonadotropins/agonists
4.
J. Health Biol. Sci. (Online) ; 9(1): 1-6, 2021. tab
Article in Portuguese | LILACS | ID: biblio-1370197

ABSTRACT

Objetivo: Avaliar o perfil e os fatores associados ao uso de anticoncepcionais orais combinados (AOC) em regimes de pausa (intermitente) ou estendido (contínuo) em mulheres férteis atendidas em um centro de planejamento familiar. Métodos: Trata-se de um estudo transversal, realizado no Centro de Pesquisa e Assistência em Reprodução Humana (CEPARH), Salvador, Bahia. Resultados: Entre julho e setembro de 2017, 210 mulheres atendidas, consecutivamente, no CEPARH foram entrevistadas. Dessas, 69 (32,8%) fazem uso de algum AOC, das quais 32 (46,4%) utilizam-no em regimes estendidos. Mulheres que trabalham têm 1,89 vezes mais chances de usarem AOC do que as que não trabalham (IC95%: 1,04-3,42; p=0,039). Nenhuma diferença significativa foi observada nas características entre as que fazem uso de AOC em regime de pausa ou estendido (p>0,05). Conclusão: Os resultados indicam que mulheres que trabalham adiam a concepção e utilizam com mais frequência a pílula contraceptiva, independentemente da forma de administração (forma contínua ou intermitente). Ademais, não há nenhum fator que contribua, significativamente, para que as mulheres façam uso estendido das cartelas de AOC.


Objective To evaluate the profile and factors associated with the use of combined oral contraceptives (COC) in pause (intermittent) or extended (continuous) regimens in fertile women attended at a family planning center. Methods: This is a cross-sectional study, carried out at the Center for Research and Assistance in Human Reproduction (CEPARH), Salvador, Bahia. Results: Between July and September 2017, 210 women consecutively attended at CEPARH were interviewed. Of these, 69 (32.8%) make use of some COC, of which 32 (46.4%) use it in extended regimens. Women who work were 1.89 times more likely to use COC than those who do not work (95%CI: 1.04-3.42; p=0.039). No significant difference was observed in characteristics among those who use COC in a paused or extended regime (p>0.05). Conclusion: The results indicate that working women postpone conception and use the contraceptive pill more frequently, regardless of the form of administration (continuous or intermittent). Moreover, there is no factor that contributes, significantly, for women to make extended use of COC cards.


Subject(s)
Contraceptive Agents , Contraceptives, Oral, Combined , Reproduction , Women , Women's Health , Fertilization , Reproductive Health , Ambulatory Care Facilities
5.
Femina ; 49(9): 572-576, 2021. ilus
Article in Portuguese | LILACS | ID: biblio-1342327

ABSTRACT

A dismenorreia é a queixa ginecológica mais comum em mulheres jovens adultas, com um índice que varia entre 43% e 93% das mulheres que menstruam. A dismenorreia membranosa (DM), uma subclassificação da dismenorreia, é definida como a descida espontânea de tecido endometrial pela vagina, cursando com dor em có- lica intensa e súbita. O relato de caso descrito evidencia três episódios típicos de DM, com recorrência em três vezes distintas, após uso do mesmo anticoncepcional oral combinado de baixa dosagem. Esta publicação é importante para a comunidade científica devido à escassez de informações e artigos científicos publicados sobre o assunto, propondo a elucidação de alguns aspectos sobre o tema.(AU)


Dysmenorrhea is the most common gynecological complaint in young adult women, with an index that varies between 43% and 93% of women who menstruate. Membranous dysmenorrhea (MD) is a subclassification of dysmenorrhea and is defined as the spontaneous descent of endometrial tissue through the vagina, leading to severe and sudden colic pain. The case report described shows three typical episodes of MD, with recurrence three times after the use of the same low-dose combined oral contraceptive. This publication is important for the scientific community due to the scarcity of information and scientific articles published about this subject, proposing to elucidate some aspects about this theme.(AU


Subject(s)
Humans , Female , Adult , Dysmenorrhea/complications , Dysmenorrhea/diagnosis , Dysmenorrhea/etiology , Dysmenorrhea/therapy , Progesterone/adverse effects , Women's Health , Contraceptives, Oral, Combined/adverse effects
6.
Int. j. cardiovasc. sci. (Impr.) ; 33(3): 208-214, May-June 2020. tab, graf
Article in English | LILACS | ID: biblio-1134363

ABSTRACT

Abstract Backgroud: Recent studies show that women on combined oral contraceptives (COC) present abnormal fasting lipid profile, increased postprandial lipemia, plasma C-reactive protein (CRP) and blood pressure (BP) compared to women not on combined oral contraceptives. Plasma renin is one of the factors responsible for abnormal BP. Objectives: To assess plasma renin levels in women using or not using COC, the correlation between renin and CRP, as well as divergences in lipid profile. Methods: A cross-sectional study with apparently healthy women aged 20 to 30, eutrophic, irregularly active, and with fasting triglycerides < 150 mg/dL. The sample was stratified into two groups: the No Combined Oral Contraceptive Group (NCOCG), comprised of women who did not use any type of hormone contraceptive, and the Combined Oral Contraceptive Group (COCG) comprised of women on low-dose COC for at least one year. After a 12-hour fast, 5 ml of blood was collected for renin dosing and PCR. Data were analyzed by the t-Test and bidirectional Mann-Whitney Test, both with significance < 0.05. Results: We evaluated 44 women equally distributed between the groups, age 23 ± 1.2 years, BMI 21.0 ± 3.2 kg/m2. Median and interquartile deviation of renin in the NCOCG and the COCG were, respectively, 0.5 (0.1-1.0) and 3.0 (2-6) (p < 0.01). A positive correlation between PCR and renin (p < 0.01 and r = 0.68) was found. Conclusion: The plasma renin levels of women using COC were higher, with a strong correlation with CRP.


Subject(s)
Humans , Female , Adult , Young Adult , Renin/drug effects , Renin/blood , Contraceptives, Oral, Combined/adverse effects , Arterial Pressure/drug effects , Renin-Angiotensin System/drug effects , Cross-Sectional Studies , Contraceptives, Oral, Combined/pharmacology , Heart Disease Risk Factors , Hypertension/etiology
9.
Rev. bras. ginecol. obstet ; 41(3): 203-205, Mar. 2019. graf
Article in English | LILACS | ID: biblio-1003537

ABSTRACT

Abstract Introduction Autoimmune progesterone dermatitis (APD) is a rare autoimmune dermatosis characterized by recurrent cutaneous and mucosal lesions during the luteal phase of the menstrual cycle that disappear some days after the menses. Case Report A 34-year-old primipara woman with no significant past medical history and no prior exogenous hormone use, who presented with cyclic skin eruptions starting 1 year after the delivery. The lesions occurred 6 days before the menses and disappeared in between 1 and 2 days after the menstruation ceased. The patient was diagnosed after a positive response to an intradermal test with progesterone and was successfully treated with combined oral contraceptives. The skin eruptions have not returned since the initiation of this therapy. Conclusion Dermatologists, gynecologists, and obstetricians should be aware of this rare entity. Furthermore, if this condition is suspected, a thorough history taking on the menstrual cycle and results of the intradermal progesterone test are mandatory.


Subject(s)
Humans , Female , Adult , Progesterone/adverse effects , Autoimmune Diseases/drug therapy , Contraceptives, Oral, Combined/administration & dosage , Dermatitis/drug therapy , Menstruation Disturbances/drug therapy , Recurrence , Autoimmune Diseases/diagnosis , Skin Tests , Treatment Outcome , Dermatitis/diagnosis , Ethinyl Estradiol/administration & dosage , Androstenes/administration & dosage , Menstruation Disturbances/diagnosis
10.
Journal of Gynecologic Oncology ; : e49-2019.
Article in English | WPRIM | ID: wpr-740192

ABSTRACT

OBJECTIVE: To evaluate the effectiveness of oral contraceptive pill (OCP) as therapy for endometrial hyperplasia (EH) without atypia in reproductive-aged women compared with oral progestin. METHODS: A retrospective cohort study was carried out in our reproductive center. Consecutive patients diagnosed with infertility and non-atypical EH identified through electronic database who met inclusion criteria (n=309). Patients were assigned to two treatment groups: OCP (n=216) and oral progestin (n=93); clinical and reproductive outcomes were recorded. RESULTS: Reversal of EH to normal endometrium, clinical pregnancy, live birth and miscarriage rate. Women in OCP group were younger, had higher prevalence of Polycystic Ovary Syndrome and other uterine pathology and longer duration of infertility than women in progestin group. Reversal of EH was observed in 93.52% women on OCP and in 86.02% women on progestin (p=0.032; adjusted odds ratio [aOR]= 2.35; 95% confidence interval [CI]=1.06-5.21) after the initial course of treatment for 2 to 6 months. Cyclic OCP (n=184) resulted in better response to treatment compared to continuous OCP (n=32) (95.11% vs. 84.38%; p=0.039; aOR =3.60; 95% CI =1.12-11.55). Clinical pregnancy rate in OCP group was marginally higher than progestin group (87/208, 41.83% vs. 27/90, 30.00%; p=0.054). Miscarriage (25.29% vs. 29.63%; p=0.654) and live birth rate (31.25% vs. 21.11%; p=0.074) were comparable between the groups. CONCLUSION: For the first time we demonstrate that OCP is an effective therapy for non-atypical EH and is associated with higher remission rate compared with oral progestin. Reproductive outcomes are reassuring and comparable between the two groups.


Subject(s)
Female , Humans , Pregnancy , Abortion, Spontaneous , Cohort Studies , Contraceptives, Oral, Combined , Drug Therapy , Endometrial Hyperplasia , Endometrium , Infertility , Live Birth , Odds Ratio , Pathology , Polycystic Ovary Syndrome , Pregnancy Rate , Prevalence , Progestins , Reproductive History , Retrospective Studies
11.
Einstein (Säo Paulo) ; 17(2): eAO4583, 2019. tab, graf
Article in English | LILACS | ID: biblio-1001910

ABSTRACT

ABSTRACT Objective: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. Methods: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. Results: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). Conclusion: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.


RESUMO Objetivo: Avaliar características clínicas e complicações em pacientes com endometriose intestinal submetidos ao tratamento hormonal. Métodos: Dados de prontuários de 238 pacientes com endometriose de retossigmoide tratadas entre maio de 2010 e maio de 2016 foram coletados para este estudo retrospectivo. Resultados: Durante o período de acompanhamento, 143 (60,1%) mulheres mantiveram tratamento clínico, enquanto 95 (39,9%) tiveram piora dos sintomas de dor ou aumento da lesão intestinal (grupo falha de tratamento clínico), sendo 54 submetidas ao tratamento cirúrgico. As mulheres no Grupo Tratamento Clínico eram mais velhas (40,5±5,1 anos versus 37,3±5,8 anos; p<0,0001) e tinham lesões intestinais menores (2,1±1,9 versus 3,1±2,2; p=0,008) em comparação ao grupo falha de tratamento clínico. Redução significativa e semelhante do escore de dor na dismenorreia, dor pélvica crônica, disquezia cíclica e disúria cíclica foi observada nos Grupos Tratamento Clínico e Cirúrgico. Dispareunia, no entato, teve uma redução maior no Grupo Cirurgia. A redução subjetiva dos sintomas dolorosos também foi semelhante entre os Grupos Clínico e Cirúrgico (100% versus 98,2%; p=0,18). O Grupo Tratamento Cirúrgico foi relacionado a uma maior taxa de complicações graves (9,2% versus 0,6%; p=0,001) em comparação ao Grupo Tratamento Clínico. Conclusão: Falha no tratamento clínico em pacientes com endometriose de retossigmoide foi observada em mulheres mais jovens que tinham lesões intestinais maiores. O tratamento clínico hormonal foi igualmente eficaz na melhora dos sintomas de dor, exceto dispareunia, em comparação ao tratamento cirúrgico em mulheres com endometriose intestinal, mas com menor taxa de complicações. O tratamento clínico deve ser oferecido como primeira opção em pacientes com endometriose intestinal, enquanto o tratamento cirúrgico deve ser reservado para pacientes sem melhora nos sintomas de dor com tratamento hormonal, progressão das lesões ou suspeita de suboclusão intestinal.


Subject(s)
Humans , Female , Adult , Progestins/therapeutic use , Rectal Diseases/drug therapy , Sigmoid Diseases/drug therapy , Pelvic Pain/drug therapy , Contraceptives, Oral, Combined/therapeutic use , Endometriosis/drug therapy , Rectal Diseases/surgery , Sigmoid Diseases/surgery , Pain Measurement , Recombinant Fusion Proteins , Medical Records , Retrospective Studies , Follow-Up Studies , Treatment Outcome , Pelvic Pain/surgery , Dysmenorrhea/drug therapy , Dyspareunia/drug therapy , Endometriosis/surgery , Chronic Pain
14.
Arq. bras. cardiol ; 111(6): 764-770, Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-973820

ABSTRACT

Abstract Background: The use of combined oral contraceptive (COC) has been related to changes in glycemic, lipid metabolism, increased oxidative stress, and systemic blood pressure, which could suggest a higher oxidation of low-density lipoprotein cholesterol (LDL-cholesterol) in women on use of COC. Objective: To test the hypothesis that there is a difference in the plasma values of oxidized LDL among women who use and do not use COC, as well as to evaluate the correlation between it and the lipid profile and high-sensitivity C-reactive protein (hs-CRP). Methods: Forty-two women with ages between 18 and 35 years old, who were eutrophic, irregularly active, with triglycerides < 150 mg/dL, blood glucose < 100 mg/dL, and who used or did not use COC were selected. These women were allocated in the COC group, formed by 21 women on COC use for at least 1 year; and a control group (CG), consisting of 21 women who had not used any type of hormonal contraceptive for at least 1 year. A significance level of 5% was adopted for statistical analyses. Results: It was observed that GCOC showed higher values of oxidized LDL than the CG, respectively 384 mU/mL versus 283 mU/mL (p < 0.01). A positive correlation between oxidized LDL and LDL-cholesterol (r = 0.3, p < 0.05), with total cholesterol (r = 0.47, p < 0.01) and with triglycerides (r = 0.32, p < 0.03) was observed, and there was no correlation with the hs-CRP. In the categorized analysis of oxidized LDL, 71.4% of GCOC women, and 28.6% of the CG remained above the established cutoff point. Conclusion: Women who use COC have higher plasma levels of oxidized LDL, and there is a positive correlation between oxidized LDL and other lipid variables.


Resumo Fundamento: O uso de contraceptivo oral combinado (COC) tem sido relacionado com alterações no metabolismo glicêmico, lipídico, maior estresse oxidativo e pressão arterial sistêmica, o que poderia sugerir maior oxidação da lipoproteína de baixa densidade colesterol (LDL-colesterol) em mulheres que utilizam COC. Objetivo: Testar a hipótese de que existe diferença nos valores plasmáticos da LDL-oxidada entre mulheres que utilizam e não utilizam COC, bem como avaliar a correlação entre ela e o perfil lipídico e proteína C reativa de alta sensibilidade (PCR-as). Métodos: Foram selecionadas 42 mulheres com idade entre 18 e 35 anos, eutróficas, irregularmente ativas, com triglicerídeos < 150 mg/dL, glicemia < 100 mg/dL e que utilizavam ou não COC. Essas foram alocadas no grupo COC, formado por 21 mulheres em uso COC há pelo menos 1 ano; e grupo controle (GC), composto por 21 mulheres que não utilizavam nenhum tipo de contraceptivo hormonal há pelo menos 1 ano. Adotado um nível de significância de 5% para as análises estatísticas. Resultados: Foi observado que o GCOC apresenta valores mais elevados da LDL-oxidada que o GC, respectivamente 384 mU/mL versus 283 mU/mL (p < 0,01). Também foi observado correlação positiva entre a LDL-oxidada e a LDL-colesterol (r = 0,3, p < 0,05), com o colesterol total (r = 0,47, p < 0,01) e com os triglicerídeos (r = 0,32, p < 0,03), não havendo correlação com a PCR-as. Na análise categorizada da LDL-oxidada, 71,4% das mulheres do GCOC e 28,6% do GC mantiveram-se acima do ponto de corte estabelecido. Conclusão: Mulheres que utilizam COC apresentam valores plasmáticos mais elevados da LDL-oxidada, existindo, correlação positiva entre a LDL-oxidada e outras variáveis lipídicas.


Subject(s)
Humans , Female , Adult , Young Adult , Contraceptives, Oral, Combined/blood , Lipoproteins, LDL/blood , Triglycerides/blood , C-Reactive Protein/analysis , Cross-Sectional Studies , Risk Factors , Oxidative Stress , Contraceptives, Oral, Combined/pharmacology , Lipoproteins, LDL/drug effects , Cholesterol, LDL/blood
16.
Bol. méd. Hosp. Infant. Méx ; 75(5): 295-302, sep.-oct. 2018. tab
Article in Spanish | LILACS | ID: biblio-1001417

ABSTRACT

Resumen: Introducción: La enfermedad renal crónica (ERC) se asocia con alteraciones menstruales, y el manejo del sangrado uterino suele ser complejo por las condiciones de este grupo de pacientes. El objetivo de este trabajo fue describir la respuesta clínica al tratamiento hormonal de las alteraciones menstruales de adolescentes con ERC. Métodos: Se presentan los datos de una serie de casos de pacientes adolescentes con ERC que cursaron con alteraciones menstruales y que recibieron tratamiento desde el año 2008 al 2012. Se identificaron las características del trastorno menstrual, del tratamiento hormonal recibido y de la respuesta al mismo. El análisis estadístico fue descriptivo. Resultados: Se estudiaron 11 pacientes de sexo femenino con edad promedio de 14.5 años, que se encontraban en prediálisis (n = 1), diálisis peritoneal (n = 7) y hemodiálisis (n = 3). Las pacientes presentaron hiperpolimenorrea asociada a la opsomenorrea (n = 3), en su mayoría clasificadas como hemorragia uterina anormal secundaria. El tratamiento, en general, fue con progestágenos de manera inicial (clormadinona con o sin medroxiprogesterona) o bien con anticonceptivos combinados. En la mayoría de las pacientes se obtuvo una respuesta favorable; sin embargo, hubo casos en los que fue necesario modificar la dosis y el tiempo de tratamiento. Conclusiones: La mayor parte de las adolescentes con ERC que han sido tratadas por hemorragia uterina anormal en nuestro estudio tuvieron una respuesta favorable al tratamiento hormonal.


Abstract: Background: Chronic kidney disease (CKD) is associated with menstrual abnormalities and management of uterine bleeding is often complex because of the conditions in this group of patients. The aim of this study was to describe the clinical response to hormonal treatment of menstrual alterations in adolescents with CKD. Methods: We present data of cases of adolescent patients with CKD who had undergone menstrual changes and received treatment during the period 2008 to 2012. The characteristics of the menstrual disorder, hormone treatment received, and response to treatment were evaluated. The statistical analysis aplicated to analyze the results was descriptive. Results: We studied 11 patients with a mean age of 14.5 years, who were in predialysis (n = 1), peritoneal dialysis (n = 7), hemodialysis (n = 3). Patients had hyperpolymenorrhea associated with opsomenorrhea (n = 3), mostly classified as secondary abnormal uterine bleeding. Treatment, in general, was with progestins initially (chlormadinone with or without medroxyprogesterone) or combined contraceptives. In the majority of the patients, a favorable response was obtained; however, there were cases where it was necessary to modify the dose and time of treatment. Conclusions: The majority of adolescents with CKD who have been treated for abnormal uterine bleeding in our study had a favorable response to hormonal treatment.


Subject(s)
Adolescent , Child , Female , Humans , Uterine Hemorrhage/etiology , Renal Insufficiency, Chronic/complications , Menstruation Disturbances/etiology , Progestins/administration & dosage , Uterine Hemorrhage/drug therapy , Chlormadinone Acetate/administration & dosage , Renal Dialysis/methods , Peritoneal Dialysis/methods , Treatment Outcome , Contraceptives, Oral, Combined/administration & dosage , Renal Insufficiency, Chronic/therapy , Medroxyprogesterone/administration & dosage , Menstruation Disturbances/drug therapy
18.
Chonnam Medical Journal ; : 153-158, 2018.
Article in English | WPRIM | ID: wpr-716581

ABSTRACT

While perimenopausal women have low fecundity, they are still capable of becoming pregnant and the majority of pregnancies occurring during perimenopause are unintended pregnancies. Therefore, even during perimenopause, contraception must be used if unintended pregnancies are to be avoided. However, many perimenopausal women and healthcare providers believe that older people should not take combined oral contraceptives (COC) because doing so may be dangerous. However, to date, there is no evidence that taking COC presents an increased risk of cardiovascular events or breast cancer for middle-aged women as compared to other age groups, and in their recommendations, the Centers for Disease Control and Prevention (CDC) also do not list age itself as a contraindication for COC. Perimenopausal women often experience menstrual irregularity, heavy menstrual bleeding, and vasomotor symptoms. Taking COCs can help control these symptoms and significantly reduce the risk of ovarian cancer, endometrial cancer, and colorectal cancer. The objective of the present review is to examine the usage methods of COC among perimenopausal women and the health issues that may arise from taking COC in perimenopausal women.


Subject(s)
Female , Humans , Pregnancy , Breast Neoplasms , Colorectal Neoplasms , Contraception , Contraceptives, Oral, Combined , Endometrial Neoplasms , Fertility , Health Personnel , Hemorrhage , Ovarian Neoplasms , Perimenopause , Risk Factors
19.
Rev. Hosp. Ital. B. Aires (2004) ; 37(1): 10-20, mar. 2017. tab
Article in Spanish | LILACS | ID: biblio-966680

ABSTRACT

El síndrome de ovario poliquísticos (SOP) representa una de las endocrinopatías más frecuentes en la mujer y es la principal causa de hiperandrogenismo (HA). Se trata de un trastorno complejo, multifactorial, poligénico con influencias ambientales. Aunque se han propuestos diferentes criterios para su diagnóstico, se prefiere el uso del más abarcativo (Criterio de Rotterdam) con la presencia de 2 de 3 de los siguientes: 1) HA clínico o bioquímico, 2) oligoanovulación crónica (OA), 3) poliquistosis ovárica por ecografía, excluyendo otras etiologías. Es frecuente su asociación con comorbilidades metabólicas (obesidad, diabetes 2, dislipidemia, apnea del sueño, etc.) y trastornos reproductivos (hiperplasia endometrial e infertilidad), sobre todo en los fenotipos clásicos, con HA y OA. El tratamiento estará orientado a las características clínicas de cada paciente y al deseo reproductivo. La pérdida de peso en aquellas con sobrepeso u obesidad o ambos factores puede restaurar los ciclos menstruales y disminuir el riesgo metabólico y representa la primera línea de tratamiento. Los anticonceptivos orales (ACO) son el tratamiento farmacológico de elección ya que atenúan las manifestaciones de HA y ofrecen protección endometrial. En las pacientes con oligoanovulación que buscan embarazo, el citrato de clomifeno es el tratamiento aconsejado en primera instancia. La metformina podría usarse en aquellas con intolerancia a la glucosa o diabetes 2 y también como segunda línea de tratamiento para restaurar los ciclos e inducir la ovulación. (AU)


Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women, the main cause of hyperandrogenism (HA). It is a complex, multifactorial polygenic disorder with environmental influences. Although there have been proposed different criteria for diagnosis, using the most comprehensive (Criteria Rotterdam) with the presence of 2 of 3 of the following is preferred: 1) HA clinical or biochemical, 2) oligo-anovulation chronic (OA), 3) polycystic ovaries by ultrasound, excluding other etiologies. It is frequently associated with metabolic comorbidities (obesity, type 2 diabetes, dyslipidemia, sleep apnea, etc.) and reproductive disorders (endometrial hyperplasia and infertility), especially in the classical phenotypes, with HA and OA. The treatment will be oriented to the clinical characteristics of each patient and reproductive desire. Weight loss in those who are overweight and / or obesity can restore menstrual cycles and decrease metabolic risk and represents the first line of treatment. Oral contraceptives (OC) are the pharmacological treatment of choice as it attenuates the manifestations of HA and offer endometrial protection. In patients seeking pregnancy with oligo-anovulation, clomiphene citrate would be used at first instance. Metformin may be used in those with impaired glucose tolerance or type 2 diabetes and also as a second-line treatment to restore cycles and induce ovulation. (AU)


Subject(s)
Humans , Female , Adolescent , Adult , Middle Aged , Young Adult , Ovulation Induction/methods , Polycystic Ovary Syndrome/diagnosis , Hyperandrogenism/etiology , Anovulation/diagnosis , Polycystic Ovary Syndrome/physiopathology , Polycystic Ovary Syndrome/drug therapy , Polycystic Ovary Syndrome/therapy , Polycystic Ovary Syndrome/diagnostic imaging , Comorbidity , Puberty/metabolism , Clomiphene/therapeutic use , Contraceptives, Oral, Combined/therapeutic use , Endometrial Hyperplasia/diagnosis , Infertility, Female/diagnosis
20.
Obstetrics & Gynecology Science ; : 232-235, 2017.
Article in English | WPRIM | ID: wpr-223106

ABSTRACT

Venous thromboembolism is well known as one of the rare but serious adverse effects of combined oral contraceptives (COCs). The COCs with third and fourth generation progestogens were found to have higher risk of venous thrombosis than those with second generation progestogens. We present a case of pulmonary embolism in a 23-year-old nulligravid woman who was using COCs containing the third generation progestogen (desogestrel). At the time of presentation of the adverse effect, she had been using the COCs for 4 months. She had no additional risk factors for thrombosis such as smoking, surgery, tumor as well as genetic factors. This case demonstrates even young women in otherwise good health may be at risk of venous thromboembolism from low-dose formulations of COCs as an over-the-counter drug. We describe this case with a brief review of literatures.


Subject(s)
Female , Humans , Young Adult , Contraceptives, Oral , Contraceptives, Oral, Combined , Desogestrel , Progestins , Pulmonary Embolism , Risk Factors , Smoke , Smoking , Thrombosis , Venous Thromboembolism , Venous Thrombosis
SELECTION OF CITATIONS
SEARCH DETAIL